Composition for inducing proliferation or accumulation of regulatory t cells

Patent metadata

Field	Value
Publication number	US-2024307463-A1
Application number	US-202418737799-A
Country	US
Kind code	A1
Filing date	Jun 7, 2024
Priority date	Jun 4, 2010
Publication date	Sep 19, 2024
Grant date	—

Abstract

It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.

First claim

What is claimed is:

1 . A method of preventing an infectious disease in a human subject in need thereof, the method comprising administering to the human subject a pharmaceutical composition comprising a spore-forming fraction of human fecal matter,
wherein the spore-forming fraction of human fecal matter induces proliferation and/or accumulation of regulatory T cells, wherein the pharmaceutical composition is formulated for oral administration.

2 . The method of claim 1 , wherein the infectious disease is a Clostridium difficile infection.

3 . The method of claim 2 , wherein the infectious disease is a recurrence of Clostridium difficile infection.

4 . The method of claim 3 , wherein the pharmaceutical composition is administered after antibiotic treatment.

5 . The method of claim 4 , wherein the pharmaceutical composition is in the form of a capsule.

6 . The method of claim 5 , wherein the pharmaceutical composition is formulated for delivery to the intestine.

7 . The method of claim 6 , wherein the pharmaceutical composition is formulated for delivery to the colon.

8 . The method of claim 7 , wherein the capsule comprises a hydrogel.

9 . The method of claim 8 , wherein the hydrogel comprises a cellulose-based polymer.

10 . The method of claim 7 , wherein the capsule comprises a pH-sensitive composition comprising one or more enteric polymers.

11 . The method of claim 7 , wherein the regulatory T cells are Foxp3 + regulatory T cells.

12 . The method of claim 11 , wherein the pharmaceutical composition does not include bacteria belonging to the genus Bacteroides.

Assignees

• Univ Tokyo

Inventors

• Honda Kenya
• Atarashi Koji
• Itoh Kikuji
• Tanoue Takeshi

Classifications

• A61K9/48

  Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)} · CPC title

• C12Q2600/158

  Expression markers · CPC title

• A61K2039/57

  characterised by the type of response, e.g. Th1, Th2 · CPC title

• A61K2039/55594

  from bacteria · CPC title

• A61K2039/542

  oral/gastrointestinal · CPC title